• Please log in or register to access this feature.

Editorial

You have full text access to this OnlineOpen article

Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution?†‡§

  1. Stephen A. Harrison M.D.¶,*

Article first published online: 30 NOV 2009

DOI: 10.1002/hep.23473

Issue

Hepatology

Hepatology

Volume 51, Issue 2, pages 366–369, February 2010

Additional Information

How to Cite

Harrison, S. A. (2010), Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution?. Hepatology, 51: 366–369. doi: 10.1002/hep.23473

Author Information

  1. Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, TX

  1. fax: 210-916-5611

*Brooke Army Medical Center, Department of Gastroenterology, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234

  1. †

    See Article on Page 445

  2. ‡

    Disclaimer statement: The opinion of ascertains contained herein are the private views of the authors and are not to be construed as official or reflecting the view of the Department of the Army or the Department of Defense.

  3. §

    Potential conflict of interest: Nothing to report.

  4. fax: 210-916-5611

Publication History

  1. Issue published online: 25 JAN 2010
  2. Article first published online: 30 NOV 2009
  3. Accepted manuscript online: 30 NOV 2009 12:00AM EST

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (75K)

References

  • 1
    Pillai AA, Rinella ME. Nonalcoholic fatty liver disease: is bariatric surgery the answer? Clin Liv Dis 2009; 13: 689–710.
  • 2
    Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis; a randomized, prospective trial. HEPATOLOGY 2009; 49: 80–86.
    Direct Link:
  • 3
    Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118.
  • 4
    Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784–1792.
  • 5
    Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297–2307.
  • 6
    Marra F, Bertolani C. Adipokines in liver disease. HEPATOLOGY 2009; 50: 957–969.
    Direct Link:
  • 7
    Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. HEPATOLOGY 2008; 47: 677–685.
    Direct Link:
  • 8
    Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547–1554.
  • 9
    Beysen C, Murphy EJ, Nagaraja H, Decaris M, Riiff T, Fong A, et al. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. J Lipid Res 2008; 49: 2657–2663.
  • 10
    Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572–2581.
  • 11
    Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561–1573.
  • 12
    Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. HEPATOLOGY 2003; 38: 1008–1017.
  • 13
    Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008; 135: 100–110.
  • 14
    Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove A, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176–1184.
  • 15
    Sanyal AJ. A randomized controlled trial of pioglitazone or vitamin E for nonalcoholic steatohepatitis (PIVENS) [Abstract]. HEPATOLOGY 2009; 50 ( Suppl.): LB4.
  • 16
    Argo CK, Northrup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371–379.
  • 17
    Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Le Naour G. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT-2) extension trial. HEPATOLOGY 2010; 51: 445–453.
  • 18
    The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet 2006; 368: 1096–1105.
  • 19
    Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517–522.
  • 20
    Lincoff A, Wolski K, Nicholls S, Nissen S. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 2007; 298: 1180–1188.
  • 21
    Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009; 104: 861–867.
  • 22
    Arslan U, Turkoglu S, Balcioglu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007; 18: 433–436.
  • 23
    Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234–238.
  • 24
    Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532–540.
View Full Article (HTML) Get PDF (75K)